Wellbutrin and Optic atrophy - a phase IV clinical study of FDA data

Summary:

Optic atrophy is reported as a side effect among people who take Wellbutrin (bupropion hydrochloride), especially for people who are female, 40-49 old, also take Aspirin, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Optic atrophy when taking Wellbutrin. It is created by eHealthMe based on reports of 101,581 people who have side effects when taking Wellbutrin from the FDA, and is updated regularly.

What is Wellbutrin?

Wellbutrin has active ingredients of bupropion hydrochloride. It is often used in depression. eHealthMe is studying from 117,107 Wellbutrin users. Check the latest studies of Wellbutrin.

What is Optic atrophy?

Optic atrophy (the loss of a proportion of optic disc nerve fibres) is found to be associated with 249 drugs and 453 conditions by eHealthMe. Check the latest studies of Optic atrophy.

On Jul, 14, 2026

101,581 people reported to have side effects when taking Wellbutrin.
Among them, 18 people (0.02%) have Optic atrophy.

Among these 18 people:

What is the gender of people who have Optic atrophy when taking Wellbutrin? *

female: 55.56 %
male: 44.44 %

What is the age of people who have Optic atrophy when taking Wellbutrin? *

What are other drugs people take besides Wellbutrin? *

What are other side effects people have besides Optic atrophy? *

Vision Blurred: 11 people, 61.11%
Balance Disorder: 9 people, 50.00%
Gait Disturbance: 7 people, 38.89%
Fatigue (feeling of tiredness): 7 people, 38.89%
Weakness: 6 people, 33.33%
Spinal Compression Fracture (fracture due to spinal compression on bone): 6 people, 33.33%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 6 people, 33.33%
Limb Discomfort (discomfort in leg): 6 people, 33.33%
Pain In Extremity: 6 people, 33.33%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 6 people, 33.33%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 6 people, 33.33%
Erection Problems: 5 people, 27.78%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 16.67%
Osteoporosis (bones weak and more likely to break): 2 people, 11.11%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 11.11%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 2 people, 11.11%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 2 people, 11.11%
Temporal Lobe Epilepsy (a term that refers to a condition where seizures are generated in the portion of the brain called the temporal lobe): 1 person, 5.56%
Neuropathy Peripheral (surface nerve damage): 1 person, 5.56%
Neuralgia (pain in one or more nerves): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Wellbutrin and have Optic atrophy?

- Check whether Optic atrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Wellbutrin:

Wellbutrin (117,107 reports)

Optic atrophy treatments and more:

Optic atrophy (2,242 reports)

Browse all side effects of Wellbutrin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Optic atrophy:

Optic atrophy (249 drugs)

Browse all the conditions that are associated with Optic atrophy:

Optic atrophy (453 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on bupropion hydrochloride (the active ingredients of Wellbutrin) and Wellbutrin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.